Endologix

Endologix, Inc. is singularly focused on providing innovative, minimally invasive technologies for aortic disorders. The Company's product offering includes a variety of endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. Designed around key issues with challenging anatomies, difficult access, and aneurysm sealing, Endologix products have been clinically proven in delivering positive patient outcomes.

Revenue(FY, 2016)

$192.9 M

Market capitalization(2018-04-25)

$351.1 M

Type

Public

Irvine, US

Founded

1992

Size (employees)

782 (est)

Website

endologix.com

Endologix was founded in 1992 and is headquartered in Irvine, US

Report incorrect company information

Key People/Management at Endologix

John McDermott

Chief Executive Officer and Director

Vaseem Mahboob

Chief Financial Officer

Michael Chobotov

Chief Technology Officer

John Onopchenko

Chief Operating Officer

Dan Lemaitre

Chairman of the Board

Matthew Thompson

Chief Medical Officer

Report incorrect company information

Endologix Office Locations

Endologix has offices in Rosmalen and Irvine

Irvine, US (HQ)

2 Musick

Rosmalen, NL

40 Burgemeester Burgerslaan

Show all (2)

Report incorrect company information

Endologix Financials and Metrics

Endologix Financials

Endologix's revenue was reported to be $192.93 m in FY, 2016 which is a 25.6% increase from the previous period.

Summary

USD
Revenue (Q2, 2017)	48.6 m
Gross profit (Q2, 2017)	32.2 m
Gross profit margin (Q2, 2017), %	66.4%
Net income (Q2, 2017)	(16.3 m)
EBIT (Q2, 2017)	(7.9 m)
Market capitalization (25-Apr-2018)	351.1 m
Cash (30-Jun-2017)	81.6 m

Endologix's current market capitalization is $351.1 m.

Income Statement

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Revenue	132.3 m	147.6 m	153.6 m	192.9 m
Revenue growth, %		12%	4%	26%
Cost of goods sold		41.8 m	51.8 m	69.1 m
Gross profit		105.8 m	101.8 m	123.8 m

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017
Revenue	33.3 m	33.3 m	38.3 m	37.2 m	36.7 m	39.5 m	38.2 m	42.4 m	51 m	52.1 m	42.6 m	48.6 m
Cost of goods sold	7.4 m	9 m	9.8 m	13.6 m	9.8 m	15.3 m	11.2 m	14.4 m	21.5 m	15.2 m	14 m	16.3 m
Gross profit	25.9 m	24.3 m	28.5 m	23.6 m	26.9 m	24.1 m	27 m	27.9 m	29.5 m	36.9 m	28.6 m	32.2 m
Gross profit Margin, %	78%	73%	74%	63%	73%	61%	71%	66%	58%	71%	67%	66%

show all

Balance Sheet

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Cash	95.2 m	26.8 m	124.6 m	26.1 m
Accounts Receivable	310 k	498 k	375 k	1.8 m
Inventories	19.6 m	31.3 m	27.9 m	41.2 m
Current Assets	173.6 m	147.8 m	237.5 m	129.8 m

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017
Cash	49.5 m	42.2 m	31.8 m	27.5 m	20.2 m	36.3 m	35.4 m	39.8 m	31.4 m	22 m	15.5 m	81.6 m
Accounts Receivable	312 k	690 k	910 k	878 k	448 k	121 k	304 k	2.6 m	825 k	659 k	952 k	390 k
Inventories	18 m	24 m	28.5 m	27.7 m	35.1 m	30.6 m	33.4 m	43.3 m	42.1 m	43.4 m	42.7 m	43.6 m
Current Assets	93.4 m	172.3 m	170.7 m	158.4 m	138.4 m	133 m	132.3 m	172.3 m	155.3 m	148.5 m	113 m	175.8 m

show all

Cash Flow

Annual

USD	FY, 2014	FY, 2015	FY, 2016
Net Income	(32.4 m)	(50.4 m)	(154.7 m)
Depreciation and Amortization	3.3 m	5.9 m	9.1 m
Inventories	(12 m)	3.5 m	3.5 m
Accounts Payable	2.7 m	8.3 m	(5.2 m)

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017
Net Income	(9 m)	5.3 m	(9 m)	(13.9 m)	(11.2 m)	(13 m)	(10.9 m)	(47.7 m)	(66.8 m)	(15.2 m)	(21.3 m)
Inventories			28.5 m	27.7 m	35.1 m	30.6 m	33.4 m	43.3 m	42.1 m	43.4 m	42.7 m
Accounts Payable			11.5 m	10.8 m	11.1 m	11.8 m	13.8 m	15.7 m	13.8 m	13 m	9.6 m